{"title":"Xanomeline-trospium可显著改善急性精神分裂症患者的认知能力","authors":"","doi":"10.1002/pu.31284","DOIUrl":null,"url":null,"abstract":"<p>The drug combining xanomeline and trospium chloride (Cobenfy®) significantly improved cognition relative to placebo in cognitively impaired adults with acute schizophrenia, a study based on data from two Phase 3 trials has found. Changes in cognition were not significantly correlated with changes in symptoms of schizophrenia, study investigators reported. Study results were published online Dec. 11, 2024, in the <i>American Journal of Psychiatry</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 4","pages":"1-5"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Xanomeline-trospium significantly improves cognition in acute schizophrenia\",\"authors\":\"\",\"doi\":\"10.1002/pu.31284\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The drug combining xanomeline and trospium chloride (Cobenfy®) significantly improved cognition relative to placebo in cognitively impaired adults with acute schizophrenia, a study based on data from two Phase 3 trials has found. Changes in cognition were not significantly correlated with changes in symptoms of schizophrenia, study investigators reported. Study results were published online Dec. 11, 2024, in the <i>American Journal of Psychiatry</i>.</p>\",\"PeriodicalId\":22275,\"journal\":{\"name\":\"The Brown University Psychopharmacology Update\",\"volume\":\"36 4\",\"pages\":\"1-5\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Brown University Psychopharmacology Update\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/pu.31284\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pu.31284","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Xanomeline-trospium significantly improves cognition in acute schizophrenia
The drug combining xanomeline and trospium chloride (Cobenfy®) significantly improved cognition relative to placebo in cognitively impaired adults with acute schizophrenia, a study based on data from two Phase 3 trials has found. Changes in cognition were not significantly correlated with changes in symptoms of schizophrenia, study investigators reported. Study results were published online Dec. 11, 2024, in the American Journal of Psychiatry.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
